Urgent(R) PC and Macroplastique(R) Featured in Numerous IUGA 2009 Sessions

MINNEAPOLIS, July 7 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a
medical device company developing, manufacturing and marketing innovative
proprietary products for the treatment of voiding dysfunctions, highlighted
today presentations, workshops and posters focusing on its solutions at the
34th Annual Meeting of the International Urogynecological Association (IUGA),
June 16-20 in Como, Italy.

Urgent PC presentations at the IUGA annual meeting included:
-- "Peripheral Tibial Neurostimulation (PTNS) (Urgent PC) Versus
Tolterodine (Detrusitol) In the Treatment Of Women With Urge Urinary
Incontinence and Urge Symptoms," presented by Oliver Preyer, M.D.
of the Department of Obstetrics and Gynecology at the University of
Vienna, Vienna, Austria, demonstrates Urgent PC has comparable
performance to Tolterodine with a significantly lower rate of side
effects.
-- "The Effects of Percutaneous Tibial Nerve Stimulation Therapy
(Neuromodulation) On Quality Of Life Of Patients With Chronic Pelvic
Pain," was presented in a poster by S.G. Bayrak, M.D. of Istanbul
University, Istanbul, Turkey, showing the treatment contributing to
the
quality of life of women with chronic pelvic pain by decreasing the
intensity of pain (this indication is not approved in the United
States).

-- A presentation by Dr. Enrico Finazzi Agro of the Department of Urology
at Tor Vergata University in Rome, Italy, featured a comparative
effectiveness study of 35 patients treated by Uroplasty's Urgent PC
system or a placebo. The study titled "Percutaneous Tibial Nerve
Stimulation (PTNS) Effects On Urge Incontinence Patients Are Not
Caused
By A Placebo Effect: A Double Blind, Placebo Controlled Study"
found urgency and frequency decreased by more than 50 percent for 64.7
percent of patients treated with Urgent PC. No patients were
considered
to have responded to the placebo.

"The 2009 Annual IUGA Meeting represents a further accumulation of clinical
evidence from leading physicians around the world supporting the ease-of-use,
safety and efficacy of our Urgent PC system for the treatment of urinary
frequency, urinary urgency and urge incontinence, symptoms often associated
with overactive bladder," said David Kaysen, President and CEO of Uroplasty,
Inc. "As this clinical evidence continues to expand, we will be presenting
this data to the medical directors of U.S. payers as part of our effort to
build awareness for reimbursement and eventually apply for a unique CPT code
for PTNS here in the U.S. In addition to Urgent PC, Macroplastique, our 'Gold
Standard' bulking agent for the treatment of adult female stress urinary
incontinence, was highlighted in several podium and poster presentations and
workshops."

Macroplastique presentations at the IUGA annual meeting included:
-- "A Cost Effective Approach To The Mid-Urethra: An Economic Analysis
Of The Use Of Bulking Agents And Mid Urethral Tapes," presented by
Dudley Robinson, M.D. of King's College Hospital in London,
England. The findings supported the use of Macroplastique or
retropubic
mid-urethral tape as cost effective treatments for stress urinary
incontinence and suggested Macroplastique may offer additional savings
in terms of cost to the healthcare system.

-- "Transurethral Injection OF Bulking Agent For The Treatment OF
Recurrent Or Persistent Female Stress Urinary Incontinence After
Mid-Urethral Sling," was presented in a poster by Dr. Y. Lee of
Samsung Medical Center of Sungkyunkwan University School of Medicine,
Seoul, South Korea, showing use of Macroplastique for a failed
mid-urethral sling produces a high patient satisfaction rate and the
procedure is minimally invasive with no significant complications.
Treatment with Macroplastique could be an option for selected patients
who have failed a mid-urethral sling with co-morbidity, operative
risks,
and for patients who want to avoid another surgery.

In addition to these various presentations, a workshop entitled "Urethral
Bulking Agents For Minimally Invasive Treatment of Stress Urinary
Incontinence," chaired by Linda Cardozo, M.D. of King's College Hospital in
London, England, drew a large physician audience. Macroplastique was
highlighted and reviewed by the physician panel, with a significant number of
positive references to safety and efficacy compared to other bulking agents.

Uroplasty also sponsored a hands-on workshop where physician attendees were
able to work with, and learn how to properly use, both Urgent PC and
Macroplastique alongside physician experts in the use of the two products.
This session drew a large audience of potential new users of both Urgent PC
and Macroplastique and received positive reviews from the attendees.

"All in all, this 34th Annual IUGA Meeting was a significant success for
Uroplasty," concluded Mr. Kaysen. "Both Urgent PC and Macroplastique were
highlighted in numerous venues which drove significant physician traffic to
our exhibit booth generating a large number of sales leads for both our
international and U.S. businesses."

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands and the United Kingdom, is a medical device
company that develops, manufactures and markets innovative proprietary
products for the treatment of voiding dysfunctions. Our primary focus is the
commercialization of our Urgent(R) PC system, which we believe is the only
FDA-approved non-surgical neurostimulation therapy for the treatment of
urinary symptoms often associated with overactive bladder (OAB). We also offer
Macroplastique(R) Implants, a urethral bulking agent for the treatment of
adult female stress urinary incontinence. Please visit Uroplasty, Inc. at
www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements, which reflect our best
estimates regarding future events and financial performance. These
forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from our anticipated results. We
discuss in detail the factors that may effect the achievement of our
forward-looking statements in our Annual Report on Form 10-K filed with the
SEC. Further, we cannot assure you that we will timely obtain, or even
succeed at all at obtaining, a specific "listed" CPT reimbursement code from
the AMA for Urgent PC treatments, and that even if we succeed at obtaining a
CPT code third-party payors will provide or continue to provide coverage and
reimbursement, or reimburse the providers an amount sufficient to cover their
costs and expenses. We further cannot assure that reimbursement or other
issues will not further impact our fiscal 2010 results.

For Further Information:
Uroplasty, Inc. EVC Group
David Kaysen, President and CEO, or Doug Sherk (Investors)
Medi Jiwani, Vice President, CFO, and Treasurer, 415.896.6820
952.426.6140 Chris Gale (Media)
646.201.5431

SOURCE Uroplasty, Inc.

David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and
Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors, Doug Sherk,
+1-415-896-6820, or Media, Chris Gale, +1-646-201-5431, both of EVC Group, for
Uroplasty, Inc.